Down syndrome, a genetic condition caused by triplication of chromosome 21, is characterized by widespread neurogenesis reduction and cognitive impairment. Unlike other brain functions, smell is not impaired at early life stages and olfactory deterioration begins to appear in adulthood. Similarly to individuals with Down syndrome, in the Ts65Dn mouse model of Down syndrome smell function is normal at early life stages. Smell impairment only appears in adulthood associated with a reduction in the number of new granule neurons migrated to the OB from the subventricular zone. Based on evidence that lithium positively impacts neurogenesis, the goal of current study was to establish whether treatment with lithium restores olfactory bulb neurogenesis and olfactory performance in middle-aged Ts65Dn mice. Euploid and Ts65Dn mice aged 13 months were treated with lithium chow or control chow for one month. Before the end of treatment, mice were injected with BrdU, in order to label proliferating cells. Results showed that in Ts65Dn mice lithium treatment restored the number of neural precursor cells in the subventricular zone of the lateral ventricle, rostral migratory stream and olfactory bulb. This effect was accompanied by restoration of olfactory performance. Unlike in olfactory neurogenic regions, treatment had no neurogenesis-enhancing effect on the subgranular zone of the hippocampal dentate gyrus, indicating that lithium has no generalized positive effect on the brain. Results suggest that lithium may have a positive impact in brain disorders that, similarly to Down syndrome, are characterized by olfactory decline and neurogenesis impairment in the subventricular zone.

Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome / Guidi, Sandra; Bianchi, Patrizia; Stagni, Fiorenza; Giacomini, Andrea; Emili, Marco; Trazzi, Stefania; Ciani, Elisabetta; Bartesaghi, Renata. - In: CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS. - ISSN 1996-3181. - STAMPA. - 16:7(2017), pp. 812-819. [10.2174/1871527315666160801143108]

Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome

GUIDI, SANDRA;BIANCHI, PATRIZIA;STAGNI, FIORENZA;GIACOMINI, ANDREA;EMILI, MARCO;TRAZZI, STEFANIA;CIANI, ELISABETTA;BARTESAGHI, RENATA
2017

Abstract

Down syndrome, a genetic condition caused by triplication of chromosome 21, is characterized by widespread neurogenesis reduction and cognitive impairment. Unlike other brain functions, smell is not impaired at early life stages and olfactory deterioration begins to appear in adulthood. Similarly to individuals with Down syndrome, in the Ts65Dn mouse model of Down syndrome smell function is normal at early life stages. Smell impairment only appears in adulthood associated with a reduction in the number of new granule neurons migrated to the OB from the subventricular zone. Based on evidence that lithium positively impacts neurogenesis, the goal of current study was to establish whether treatment with lithium restores olfactory bulb neurogenesis and olfactory performance in middle-aged Ts65Dn mice. Euploid and Ts65Dn mice aged 13 months were treated with lithium chow or control chow for one month. Before the end of treatment, mice were injected with BrdU, in order to label proliferating cells. Results showed that in Ts65Dn mice lithium treatment restored the number of neural precursor cells in the subventricular zone of the lateral ventricle, rostral migratory stream and olfactory bulb. This effect was accompanied by restoration of olfactory performance. Unlike in olfactory neurogenic regions, treatment had no neurogenesis-enhancing effect on the subgranular zone of the hippocampal dentate gyrus, indicating that lithium has no generalized positive effect on the brain. Results suggest that lithium may have a positive impact in brain disorders that, similarly to Down syndrome, are characterized by olfactory decline and neurogenesis impairment in the subventricular zone.
2017
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome / Guidi, Sandra; Bianchi, Patrizia; Stagni, Fiorenza; Giacomini, Andrea; Emili, Marco; Trazzi, Stefania; Ciani, Elisabetta; Bartesaghi, Renata. - In: CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS. - ISSN 1996-3181. - STAMPA. - 16:7(2017), pp. 812-819. [10.2174/1871527315666160801143108]
Guidi, Sandra; Bianchi, Patrizia; Stagni, Fiorenza; Giacomini, Andrea; Emili, Marco; Trazzi, Stefania; Ciani, Elisabetta; Bartesaghi, Renata
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/612123
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact